icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
June 23-26 2021
Back grey_arrow_rt.gif
 
 
 
Treatment with GSK3228836 leads to HBsAg reduction
and induction of interferon gamma related proteins
and chemokines in a Phase 2a, randomized,
double-blind, placebo-controlled study

 
 
  EASL International Liver Congress, June 23-26, 2021
 
Shihyun You1, Jennifer Singh1, Susan Smith1, William Jordan1, Katja Remlinger2, Shilpy Joshi1, Megan Ermler1, Jared Delahaye1, Adam Taylor3, Sutirtha Chakraborty4, Dhyanesh Srivastava5, Melanie Paff1, Dickens Theodore2
 
1GlaxoSmithKline, Collegeville, PA, USA; 2GlaxoSmithKline, Research Triangle Park, NC, USA; 3GlaxoSmithKline, Stevenage, UK; 4GlaxoSmithKline, Bangalore, India; 5GlaxoSmithKline, Noida, India

0628211

0628212

0628213

0628214

0628215

0628216

0628217

0628218

0628219